共 50 条
GB virus type C E2 protein inhibits human immunodeficiency virus type 1 Gag assembly by downregulating human ADP-ribosylation factor 1
被引:4
|作者:
Wang, Chenliang
[1
,2
,3
,4
]
Timmons, Christine L.
[1
]
Shao, Qiujia
[1
]
Kinlock, Ballington L.
[1
]
Turner, Tiffany M.
[1
]
Iwamoto, Aikichi
[5
]
Zhang, Hui
[2
,3
,4
]
Liu, Huanliang
[2
,3
,4
]
Liu, Bindong
[1
]
机构:
[1] Meharry Med Coll, Dept Microbiol & Immunol, Ctr AIDS Hlth Dispar Res, Nashville, TN 37208 USA
[2] Sun Yat Sen Univ, Guangdong Prov Key Lab Colorectal & Pelv Floor Di, Guangdong Inst Gastroenterol, Dept Clin Lab, Guangzhou 510275, Guangdong, Peoples R China
[3] Sun Yat Sen Univ, Inst Human Virol, Affiliated Hosp 6, Guangzhou 510275, Guangdong, Peoples R China
[4] Sun Yat Sen Univ, Key Lab Trop Dis Control, Minist Educ, Guangzhou 510275, Guangdong, Peoples R China
[5] Univ Tokyo, Inst Med Sci, Div Infect Dis, Adv Clin Res Ctr, Tokyo, Japan
来源:
基金:
美国国家卫生研究院;
关键词:
GBV-C E2;
HIV-1;
assembly;
Gag;
plasma membrane targeting;
ARF1;
Immunology and Microbiology Section;
Immune response;
Immunity;
TO-GOLGI TRANSPORT;
ENDOPLASMIC-RETICULUM;
GLYCOPROTEIN E2;
BREFELDIN-A;
HIV-1;
GAG;
ENTRY INHIBITION;
PLASMA-MEMBRANE;
AMINO-TERMINUS;
LIVING CELLS;
ARF PROTEINS;
D O I:
10.18632/oncotarget.6537
中图分类号:
R73 [肿瘤学];
学科分类号:
100214 ;
摘要:
GB virus type C (GBV-C) glycoprotein E2 protein disrupts HIV-1 assembly and release by inhibiting Gag plasma membrane targeting, however the mechanism by which the GBV-C E2 inhibits Gag trafficking remains unclear. In the present study, we identified ADP-ribosylation factor 1 (ARF1) contributed to the inhibitory effect of GBV-C E2 on HIV-1 Gag membrane targeting. Expression of GBV-C E2 decreased ARF1 expression in a proteasomal degradation-dependent manner. The restoration of ARF1 expression rescued the HIV-1 Gag processing and membrane targeting defect imposed by GBV-C E2. In addition, GBV-C E2 expression also altered Golgi morphology and suppressed protein traffic through the secretory pathway, which are all consistent with a phenotype of disrupting the function of ARF1 protein. Thus, our results indicate that GBV-C E2 inhibits HIV-1 assembly and release by decreasing ARF1, and may provide insights regarding GBV-C E2's potential for a new therapeutic approach for treating HIV-1.
引用
下载
收藏
页码:43293 / 43309
页数:17
相关论文